vs
LOUISIANA-PACIFIC CORP（LPX）与莫德纳（MRNA）财务数据对比。点击上方公司名可切换其他公司
莫德纳的季度营收约是LOUISIANA-PACIFIC CORP的1.8倍（$1.0B vs $566.0M），LOUISIANA-PACIFIC CORP净利率更高（-1.4% vs -19.7%，领先18.3%），LOUISIANA-PACIFIC CORP同比增速更快（-16.9% vs -45.4%），LOUISIANA-PACIFIC CORP自由现金流更多（$-8.0M vs $-880.0M），过去两年LOUISIANA-PACIFIC CORP的营收复合增速更高（-11.6% vs -45.0%）
路易斯安那-太平洋公司（简称LP）是美国知名建材制造商，成立于1973年，是美国定向结构刨花板（OSB）生产的开创者，总部现位于田纳西州纳什维尔。作为全球最大的OSB生产商，公司还生产工程木建材产品，通过建材分销商、经销商及家居零售中心向建筑商和业主供货。
莫德纳是一家总部位于美国马萨诸塞州剑桥市的生物制药企业，深耕RNA治疗领域，核心业务聚焦mRNA疫苗研发。其疫苗通过信使RNA（mRNA）分子拷贝传递蛋白合成指令以触发人体免疫反应，公司名称由“修饰”“RNA”与“现代”三个词组合而来。
LPX vs MRNA — 直观对比
营收规模更大
MRNA
是对方的1.8倍
$566.0M
营收增速更快
LPX
高出28.5%
-45.4%
净利率更高
LPX
高出18.3%
-19.7%
自由现金流更多
LPX
多$872.0M
$-880.0M
两年增速更快
LPX
近两年复合增速
-45.0%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $566.0M | $1.0B |
| 净利润 | $-8.0M | $-200.0M |
| 毛利率 | 15.0% | 79.6% |
| 营业利润率 | -1.6% | -25.6% |
| 净利率 | -1.4% | -19.7% |
| 营收同比 | -16.9% | -45.4% |
| 净利润同比 | -112.9% | -1638.5% |
| 每股收益（稀释后） | $-0.12 | $-0.51 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LPXMRNA
| Q4 25 | $566.0M | — | ||
| Q3 25 | $663.0M | $1.0B | ||
| Q2 25 | $755.0M | — | ||
| Q1 25 | $724.0M | — | ||
| Q4 24 | $681.0M | $966.0M | ||
| Q3 24 | $722.0M | $1.9B | ||
| Q2 24 | $814.0M | — | ||
| Q1 24 | $724.0M | — |
净利润LPXMRNA
| Q4 25 | $-8.0M | — | ||
| Q3 25 | $9.0M | $-200.0M | ||
| Q2 25 | $54.0M | — | ||
| Q1 25 | $91.0M | — | ||
| Q4 24 | $62.0M | $-1.1B | ||
| Q3 24 | $90.0M | $13.0M | ||
| Q2 24 | $160.0M | — | ||
| Q1 24 | $108.0M | — |
毛利率LPXMRNA
| Q4 25 | 15.0% | — | ||
| Q3 25 | 19.5% | 79.6% | ||
| Q2 25 | 23.6% | — | ||
| Q1 25 | 27.2% | — | ||
| Q4 24 | 23.8% | 23.5% | ||
| Q3 24 | 26.7% | 72.4% | ||
| Q2 24 | 32.3% | — | ||
| Q1 24 | 29.6% | — |
营业利润率LPXMRNA
| Q4 25 | -1.6% | — | ||
| Q3 25 | 2.7% | -25.6% | ||
| Q2 25 | 10.6% | — | ||
| Q1 25 | 16.6% | — | ||
| Q4 24 | 11.0% | -129.0% | ||
| Q3 24 | 16.1% | -3.8% | ||
| Q2 24 | 23.8% | — | ||
| Q1 24 | 20.0% | — |
净利率LPXMRNA
| Q4 25 | -1.4% | — | ||
| Q3 25 | 1.4% | -19.7% | ||
| Q2 25 | 7.2% | — | ||
| Q1 25 | 12.6% | — | ||
| Q4 24 | 9.1% | -115.9% | ||
| Q3 24 | 12.5% | 0.7% | ||
| Q2 24 | 19.7% | — | ||
| Q1 24 | 14.9% | — |
每股收益（稀释后）LPXMRNA
| Q4 25 | $-0.12 | — | ||
| Q3 25 | $0.13 | $-0.51 | ||
| Q2 25 | $0.77 | — | ||
| Q1 25 | $1.30 | — | ||
| Q4 24 | $0.90 | $-2.91 | ||
| Q3 24 | $1.28 | $0.03 | ||
| Q2 24 | $2.23 | — | ||
| Q1 24 | $1.48 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $292.0M | $1.1B |
| 总债务越低越好 | $348.0M | — |
| 股东权益账面价值 | $1.7B | $9.3B |
| 总资产 | $2.6B | $12.1B |
| 负债/权益比越低杠杆越低 | 0.20× | — |
8季度趋势，按日历期对齐
现金及短期投资LPXMRNA
| Q4 25 | $292.0M | — | ||
| Q3 25 | $316.0M | $1.1B | ||
| Q2 25 | $333.0M | — | ||
| Q1 25 | $256.0M | — | ||
| Q4 24 | $340.0M | $1.9B | ||
| Q3 24 | $346.0M | $1.6B | ||
| Q2 24 | $317.0M | — | ||
| Q1 24 | $244.0M | — |
总债务LPXMRNA
| Q4 25 | $348.0M | — | ||
| Q3 25 | $348.0M | — | ||
| Q2 25 | $348.0M | — | ||
| Q1 25 | $348.0M | — | ||
| Q4 24 | $348.0M | — | ||
| Q3 24 | $347.0M | — | ||
| Q2 24 | $347.0M | — | ||
| Q1 24 | $347.0M | — |
股东权益LPXMRNA
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.7B | $9.3B | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $1.7B | $10.9B | ||
| Q3 24 | $1.7B | $11.9B | ||
| Q2 24 | $1.7B | — | ||
| Q1 24 | $1.6B | — |
总资产LPXMRNA
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | $12.1B | ||
| Q2 25 | $2.7B | — | ||
| Q1 25 | $2.6B | — | ||
| Q4 24 | $2.6B | $14.1B | ||
| Q3 24 | $2.6B | $15.8B | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.5B | — |
负债/权益比LPXMRNA
| Q4 25 | 0.20× | — | ||
| Q3 25 | 0.20× | — | ||
| Q2 25 | 0.20× | — | ||
| Q1 25 | 0.21× | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 0.21× | — | ||
| Q2 24 | 0.21× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $67.0M | $-847.0M |
| 自由现金流经营现金流 - 资本支出 | $-8.0M | $-880.0M |
| 自由现金流率自由现金流/营收 | -1.4% | -86.6% |
| 资本支出强度资本支出/营收 | 13.3% | 3.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $91.0M | $-1.9B |
8季度趋势，按日历期对齐
经营现金流LPXMRNA
| Q4 25 | $67.0M | — | ||
| Q3 25 | $89.0M | $-847.0M | ||
| Q2 25 | $162.0M | — | ||
| Q1 25 | $64.0M | — | ||
| Q4 24 | $105.0M | $825.0M | ||
| Q3 24 | $183.0M | $-1.6B | ||
| Q2 24 | $212.0M | — | ||
| Q1 24 | $105.0M | — |
自由现金流LPXMRNA
| Q4 25 | $-8.0M | — | ||
| Q3 25 | $5.0M | $-880.0M | ||
| Q2 25 | $94.0M | — | ||
| Q1 25 | $0 | — | ||
| Q4 24 | $43.0M | $303.0M | ||
| Q3 24 | $139.0M | $-1.7B | ||
| Q2 24 | $176.0M | — | ||
| Q1 24 | $64.0M | — |
自由现金流率LPXMRNA
| Q4 25 | -1.4% | — | ||
| Q3 25 | 0.8% | -86.6% | ||
| Q2 25 | 12.5% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 6.3% | 31.4% | ||
| Q3 24 | 19.3% | -92.2% | ||
| Q2 24 | 21.6% | — | ||
| Q1 24 | 8.8% | — |
资本支出强度LPXMRNA
| Q4 25 | 13.3% | — | ||
| Q3 25 | 12.7% | 3.2% | ||
| Q2 25 | 9.0% | — | ||
| Q1 25 | 8.8% | — | ||
| Q4 24 | 9.1% | 54.0% | ||
| Q3 24 | 6.1% | 8.1% | ||
| Q2 24 | 4.4% | — | ||
| Q1 24 | 5.7% | — |
现金转化率LPXMRNA
| Q4 25 | — | — | ||
| Q3 25 | 9.89× | — | ||
| Q2 25 | 3.00× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 1.69× | — | ||
| Q3 24 | 2.03× | -120.46× | ||
| Q2 24 | 1.32× | — | ||
| Q1 24 | 0.97× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LPX
| OS Bvalueadd | $472.0M | 83% |
| Other | $84.0M | 15% |
| Otherproducts | $10.0M | 2% |
MRNA
| COVID19 | $971.0M | 96% |
| Other Revenue | $20.0M | 2% |
| Grant | $14.0M | 1% |
| Collaboration Arrangement Including Arrangements With Affiliate | $7.0M | 1% |
| License And Royalty | $2.0M | 0% |
